Navidea biopharmaceuticals announces the notice of allowance for u.s. patent application for diagnosis and treatment of leishmaniasis

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it has received a notice of allowance for the patent application titled, “compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same” (u.s. patent application no. 15/729,633). navidea also announced that it has received
NAVB Ratings Summary
NAVB Quant Ranking